Literature DB >> 25267892

Paroxetine versus other anti-depressive agents for depression.

Andrea Cipriani1, Toshi A Furukawa2, Antonio Veronese3, Norio Watanabe2, Rachel Churchill4, Hugh McGuire5, Corrado Barbui1.   

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of major depressive disorder.To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents.

Entities:  

Year:  2007        PMID： 25267892      PMCID： PMC4176672          DOI： 10.1002/14651858.CD006531

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN： 1361-6137


  37 in total

1.  Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports.

Authors:  Arif Khan; Shirin R Khan; Gary Walens; Russell Kolts; Earl L Giller
Journal:  Neuropsychopharmacology       Date:  2002-09-16       Impact factor: 7.853

2.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

Authors:  Bodil Als-Nielsen; Wendong Chen; Christian Gluud; Lise L Kjaergard
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

3.  Clinician's judgments of mental health.

Authors:  L LUBORSKY
Journal:  Arch Gen Psychiatry       Date:  1962-12

Review 4.  "Wish bias" in antidepressant drug trials?

Authors:  Corrado Barbui; Andrea Cipriani; Paolo Brambilla; Matthew Hotopf
Journal:  J Clin Psychopharmacol       Date:  2004-04       Impact factor: 3.153

Review 5.  Industry sponsorship and authorship of clinical trials over 20 years.

Authors:  Susan S Buchkowsky; Peter J Jewesson
Journal:  Ann Pharmacother       Date:  2004-02-24       Impact factor: 3.154

6.  Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.

Authors:  Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux
Journal:  CMAJ       Date:  2004-02-17       Impact factor: 8.262

Review 7.  Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

Authors:  Richard A Hansen; Gerald Gartlehner; Kathleen N Lohr; Bradley N Gaynes; Timothy S Carey
Journal:  Ann Intern Med       Date:  2005-09-20       Impact factor: 25.391

8.  Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses.

Authors:  Toshiaki A Furukawa; Gordon H Guyatt; Lauren E Griffith
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

Review 9.  Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

Authors:  David Smith; Carrie Dempster; Julie Glanville; Nick Freemantle; Ian Anderson
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

10.  Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.

Authors:  Mark Zimmerman; Michael A Posternak; Iwona Chelminski
Journal:  J Psychiatr Res       Date:  2004 Nov-Dec       Impact factor: 4.791
View more
  2 in total

Review 1.  Mirtazapine versus other antidepressive agents for depression.

Authors:  Norio Watanabe; Ichiro M Omori; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  New generation antidepressants for depression in children and adolescents: a network meta-analysis.

Authors:  Sarah E Hetrick; Joanne E McKenzie; Alan P Bailey; Vartika Sharma; Carl I Moller; Paul B Badcock; Georgina R Cox; Sally N Merry; Nicholas Meader
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.